1. Home
  2. BLX vs LQDA Comparison

BLX vs LQDA Comparison

Compare BLX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLX
  • LQDA
  • Stock Information
  • Founded
  • BLX 1977
  • LQDA 2004
  • Country
  • BLX Panama
  • LQDA United States
  • Employees
  • BLX N/A
  • LQDA N/A
  • Industry
  • BLX Commercial Banks
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLX Finance
  • LQDA Health Care
  • Exchange
  • BLX Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • BLX 1.6B
  • LQDA 1.7B
  • IPO Year
  • BLX N/A
  • LQDA 2018
  • Fundamental
  • Price
  • BLX $45.95
  • LQDA $26.84
  • Analyst Decision
  • BLX
  • LQDA Strong Buy
  • Analyst Count
  • BLX 0
  • LQDA 10
  • Target Price
  • BLX N/A
  • LQDA $31.40
  • AVG Volume (30 Days)
  • BLX 126.9K
  • LQDA 3.2M
  • Earning Date
  • BLX 08-04-2025
  • LQDA 08-12-2025
  • Dividend Yield
  • BLX 5.43%
  • LQDA N/A
  • EPS Growth
  • BLX 12.91
  • LQDA N/A
  • EPS
  • BLX 5.97
  • LQDA N/A
  • Revenue
  • BLX $306,166,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • BLX $13.23
  • LQDA $190.73
  • Revenue Next Year
  • BLX $7.79
  • LQDA $421.01
  • P/E Ratio
  • BLX $7.61
  • LQDA N/A
  • Revenue Growth
  • BLX 12.96
  • LQDA 30.20
  • 52 Week Low
  • BLX $29.55
  • LQDA $8.75
  • 52 Week High
  • BLX $47.43
  • LQDA $28.00
  • Technical
  • Relative Strength Index (RSI)
  • BLX 64.41
  • LQDA 74.95
  • Support Level
  • BLX $44.48
  • LQDA $26.47
  • Resistance Level
  • BLX $45.26
  • LQDA $27.88
  • Average True Range (ATR)
  • BLX 1.12
  • LQDA 1.44
  • MACD
  • BLX 0.19
  • LQDA 0.35
  • Stochastic Oscillator
  • BLX 78.20
  • LQDA 87.08

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: